Cantor Fitzgerald Reiterates Overweight Rating for Xenon Pharmaceuticals (NASDAQ:XENE)

Xenon Pharmaceuticals (NASDAQ:XENE)‘s stock had its “overweight” rating reaffirmed by investment analysts at Cantor Fitzgerald in a report issued on Friday, Benzinga reports. They presently have a $65.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 63.73% from the stock’s previous close.

XENE has been the topic of a number of other research reports. Citigroup cut their price target on shares of Xenon Pharmaceuticals from $62.00 to $60.00 and set a “buy” rating on the stock in a report on Friday, May 10th. Royal Bank of Canada reiterated an “outperform” rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a research note on Tuesday, June 18th. Needham & Company LLC restated a “buy” rating and issued a $62.00 price target on shares of Xenon Pharmaceuticals in a research note on Friday, May 10th. Finally, Wedbush lowered their price target on Xenon Pharmaceuticals from $50.00 to $49.00 and set an “outperform” rating on the stock in a report on Friday. One investment analyst has rated the stock with a sell rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, Xenon Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $59.00.

Xenon Pharmaceuticals Trading Down 3.2 %

Xenon Pharmaceuticals stock traded down $1.31 during mid-day trading on Friday, hitting $39.70. The company had a trading volume of 399,057 shares, compared to its average volume of 404,791. Xenon Pharmaceuticals has a 12 month low of $27.99 and a 12 month high of $50.99. The stock’s 50 day moving average price is $39.71 and its two-hundred day moving average price is $42.27. The company has a market capitalization of $3.00 billion, a PE ratio of -14.65 and a beta of 1.26.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.03). During the same period in the prior year, the company posted ($0.72) EPS. Equities research analysts anticipate that Xenon Pharmaceuticals will post -2.98 EPS for the current year.

Institutional Investors Weigh In On Xenon Pharmaceuticals

A number of large investors have recently made changes to their positions in XENE. Tower Research Capital LLC TRC lifted its stake in shares of Xenon Pharmaceuticals by 414.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,014 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 817 shares during the period. Parallel Advisors LLC increased its holdings in Xenon Pharmaceuticals by 51.2% during the fourth quarter. Parallel Advisors LLC now owns 1,125 shares of the biopharmaceutical company’s stock valued at $52,000 after buying an additional 381 shares during the last quarter. PNC Financial Services Group Inc. bought a new position in Xenon Pharmaceuticals in the fourth quarter worth approximately $91,000. 17 Capital Partners LLC bought a new stake in shares of Xenon Pharmaceuticals during the 1st quarter valued at $122,000. Finally, EntryPoint Capital LLC purchased a new stake in shares of Xenon Pharmaceuticals in the 1st quarter worth $195,000. 95.45% of the stock is currently owned by institutional investors.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.